TABLE 1.
Baseline characteristics
| Participants (N = 95) | |
|---|---|
| Sex, n (%) | |
| Female | 76 (80.0) |
| Male | 19 (20.0) |
| Age at enrollment (years) | |
| Mean (SD) | 41.4 (11.3) |
| Median (IQR) | 42.8 (32.1, 50.8) |
| Number missing | 0 |
| Age at migraine onset (years) | |
| Mean (SD) | 19.4 (10.7) |
| Median (IQR) | 17.4 (11.8, 24.5) |
| Number missing | 0 |
| Age at migraine diagnosis (years) | |
| Mean (SD) | 27.1 (10.9) |
| Median (IQR) | 26.5 (19.5, 33.8) |
| Number missing | 2 |
| Migraine type, n (%) | |
| Chronic migraine | 64 (67.4) |
| Episodic migraine | 31 (32.6) |
| Erenumab dose at initiation, n (%) | |
| 70 mg | 6 (6.3) |
| 140 mg | 89 (93.7) |
| Medication overuse during screening period, n (%) | |
| No | 27 (28.4) |
| Yes | 68 (71.6) |
| Migraine with aura, n (%) | |
| Never | 36 (37.9) |
| Rarely | 17 (17.9) |
| Unsure | 1 (1.1) |
| Yes—always | 9 (9.5) |
| Yes—sometimes | 32 (33.7) |
| Number of prior categories of prophylactic migraine therapies with inadequate efficacy, n (%) | |
| 2 | 52 (54.7) |
| 3 | 31 (32.6) |
| 4 | 11 (11.6) |
| 5 | 0 (0.0) |
| 6 | 1 (1.1) |
| Type of prior categories of prophylactic migraine therapies with inadequate efficacy, n (%) | |
| Divalproex sodium, sodium valproate | 3 (3.2) |
| Topiramate | 64 (67.4) |
| Beta blockers | 41 (43.2) |
| Tricyclic antidepressants and venlafaxine | 78 (82.1) |
| Flunarizine or verapamil | 12 (12.6) |
| Candesartan or lisinopril | 28 (29.5) |
| Pizotifen | 1 (1.1) |
| Botulinum toxin | 20 (21.1) |
Abbreviations: IQR, interquartile range; SD, standard deviation.